RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Ereditarietà, cancerogenesi e progressione tumorale del carcinoma gastrico
• 2 - Carcinoma gastrico e infezione da Helicobacter pylori: importanza del genotipo, delle attività enzimatiche e del proteoma batterici e di fattori ospite-correlati, quali il polimorfismo genetico delle citochine infiammatorie e dei perossisomi e l'espressione di oncogeni, geni oncosoppressori e molecole d'adesione.
• 3 - Metastasi epatiche da cancro del colon-retto: fattori di rischio, prognosi e trattamento su basi molecolari
• 4 - MECCANISMI MOLECOLARI DI CHEMIOPREVENZIONE E CHEMIORESISTENZA NELLA CARCINOGENESI GASTRICA CORRELATA ALL'INFEZIONE DA HELICOBACTER PYLORI
• 5 - RUOLO DELLA FARMACOGENETICA NELLA DEFINIZIONE DELL'ATTIVITA' E TOLLERABILITA' DELLA CHEMIOTERAPIA ANTINEOPLASTICA
• 6 - Valutazione della risposta tumorale con parametri biologici, immunologici e di imaging funzionale
• 7 - RUOLO DELLE CELLULE DELLA IMMUNITA' INNATA NELLA PATOGENESI DELLA MALATTIA DA HELICOBACTER PYLORI
• 8 - PROGRESSIONE DA MGUS A MIELOMA MULTIPLO: PATOGENESI MOLECOLARE, IDENTIFICAZIONE DI POTENZIALI MARCATORI PROGNOSTICI E SVILUPPO PRECLINICO DI RAZIONALI APPROCCI CHEMIOPREVENTIVI
• 9 - Fisiopatologia,clinica e terapia dei tumori corticosurrenalici
• 10 - IDENTIFICAZIONE DI FATTORI MOLECOLARI PER LA VALUTAZIONE DEL RISCHIO METASTATICO NEI CARCINOMI COLORETTALI

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • ONCOLOGIA MEDICA
  • ANATOMIA PATOLOGICA
  • GASTROENTEROLOGIA
  • CHIRURGIA GENERALE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Veneto

Bibliografia

1) Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30.
2) El-Rifai W, Powell SM. Molecular biology of gastric cancer.
Semin Radiat Oncol. 2002 Apr;12(2):128-40.
3) de Manzoni G, Tomezzoli A, Di Leo A, Moore PS, Talamini G, Scarpa A. Clinical significance of mutator phenotype and chromosome 17p and 18q allelic loss in gastric cancer. Br J Surg. 2001 Mar;88(3):419-25.
4)Halling KC, Harper J, Moskaluk CA, Thibodeau SN, Petroni GR, Yustein AS, Tosi P, Minacci C, Roviello F, Piva P, Hamilton SR, Jackson CE, Powell SM. Origin of microsatellite instability in gastric cancer. Am J Pathol 1999; 155:205-11.
5)Yamamoto H, Perez-Piteira J, Yoshida T, Terada M, Itoh F, Imai K, Perucho M. Gastric cancers of the microsatellite mutator phenotype display characteristic genetic and clinical features. Gastroenterology 1999; 116:1348-57.
6) Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman D, Pharoah PD, Jankowski JA, Mac Leod P, Roviello F. Familial gastric cancer: overview and guidelines for management. J Med Genetics 1999; 36:873-80.
7) Crowe SE. Helicobacter infection, chronic inflammation, and the development of malignancy. Curr Opin Gastroenterol. 2005 Jan;21(1):32-8.
8) Ernst P. The role of inflammation in the pathogenesis of gastric cancer. Aliment Pharmacol Ther. 1999 Mar;13 Suppl 1:13-8.
9) Yang SM, Fang DC, Luo YH, Lu R, Battle PD, Liu WW. Alterations of telomerase activity and terminal restriction fragment in gastric cancer and its premalignant lesions. J Gastroenterol Hepatol. 2001 Aug;16(8):876-82.
10)Yang SM, Fang DC, Luo YH, Lu R, Battle PD, Liu WW. Alterations of telomerase activity and terminal restriction fragment in gastric cancer and its premalignant lesions. J Gastroenterol Hepatol. 2001 Aug;16(8):876-82.
11) Cassaro M, Pennelli G, Rugge M, Farinati F, Zaninotto G. Gastric precancerous lesion follow up based on pathological evidence. J Clin Pathol. 2004 Sep;57(9):1007-8.
12) Farinati F, Cardin R, Russo VM, Busatto G, Franco M, Falda A, Mescoli C, Rugge M. Differential effects of Helicobacter pylori eradication on oxidative DNA damage at the gastroesophageal junction and at the gastric antrum. Cancer Epidemiol Biom & Prev 2004; 13: 1722-1728
13) Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg. 2005 Jan;241(1):27-39.
14) Macdonald JS. Treatment of localized gastric cancer. Semin Oncol. 2004 Aug;31(4):566-73.
15) Marrelli M, Roviello F, De Manzoni G. Prediction of recurrence aftre radical surgery for gastric cancer. A scoring system obtained from a prospective multicentre study. Ann Surg 2004. ISSN: 0003-4932
16) Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev. 2004 Aug;30(5):451-9.
17)Mocellin S, Del Fiore P, Guarnieri L, Scalerta R, Foletto M, Chiarion V, Pilati P, Nitti D, Lise M, Rossi CR. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 2004 Sep 20;111(5):741-5.
18) Miyazono F, Natsugoe S, Takao S, Tokuda K, Kijima F, Aridome K, Hokita S, Baba M, Eizuru Y, Aikou T. Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann Surg. 2001 Feb;233(2):189-94.
19) Mocellin S, Provenzano M, Rossi CR, Pilati P, Nitti D, Lise M. DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. Ann Surg. 2005 Jan;241(1):16-26.
20) D'Arrigo A, Belluco C, Ambrosi A, Digito M, Esposito G, Bertola A, Fabris M, Nofrate V, MammanoE, Leon A, Nitti D, Lise M. Metastatic transcriptional pattern revealed by gene expression profiling in primary colorectal carcinoma. Int J Cancer. 2005 Jun 1;115(2):256-62.
21) Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M, Scarpa A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta. 2004 Sep 17;1693(3):167-76.
22) Mocellin S, Rossi CR, Traldi P, Nitti D, Lise M. Molecular oncology in the post-genomic era: the challenge of proteomics.
Trends Mol Med. 2004 Jan;10(1):24-32.
23) Seraglia R, Ragazzi E, Vogliardi S, Allegri G, Pucciarelli S, Agostini M, Lise M, Nitti D, Urso ED, Traldi P. Search of plasma markers for colorectal cancer by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom. 2005 Jan;40(1):12-16.
24) Shergill IS, Shergill NK, Arya M, Patel HR. Tissue microarrays: a current medical research tool. Curr Med Res Opin. 2004 May;20 :707-12.
25) Simon R, Mirlacher M, Sauter G. Tissue microarrays. Biotechniques. 2004 Jan;36(1):98-105.

Parole Chiave

CARCINOMA GASTRICO; CANCEROGENESI; LESIONI PRENEOPLASTICHE; GENETICA; TERAPIA GENICA; FATTORI PROGNOSTICI; RISPOSTA AL TRATTAMENTO; MICROARRAY; PROTEOMICA